http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Kim Joon‐ (검색결과 99 건)
- 무료
- 기관 내 무료
- 유료
-
Confidence limits for patient‐specific IMRT dose QA: a multi‐institutional study in Korea
Kim, Jung‐,in,Chung, Jin‐,Beom,Song, Ju‐,Young,Kim, Sung Kyu,Choi, Yunseok,Choi, Chang Heon,Choi, Won Hoon,Cho, Byungchul,Kim, Jin Sung,Kim, Sung Jin,Ye, Sung‐,Joon John Wiley and Sons Inc. 2016 Journal of applied clinical medical physics Vol.17 No.1
<P>This study aims to investigate tolerance levels for patient‐specific IMRT dose QA (DQA) using the confidence limits (CL) determined by a multi‐institutional study. Eleven institutions participated in the multi‐institutional study in Korea. A total of 155 DQA measurements, consisting of point‐dose differences (high‐ and low‐dose regions) and gamma passing rates (composite and per‐field) for IMRT patients with brain, head and neck (H&N), abdomen, and prostate cancers were examined. The Shapiro‐Wilk test was used to evaluate the normality of data grouped by the treatment sites and the DQA methods. The confidence limit coefficients in cases of the normal distribution, and the two‐sided Student's <I>t</I>‐distribution were applied to determine the confidence limits for the grouped data. The Spearman's test was applied to assess the sensitivity of DQA results within the limited groups. The differences in CLs between the two confidence coefficients based on the normal and <I>t</I>‐distributions were negligible for the point‐dose data and the gamma passing rates with 3%/3 criteria. However, with 2%/2 criteria, the difference in CLs were 1.6% and 2.2% for composite and per‐field measurements, respectively. This resulted from the large standard deviation and the more sensitive criteria of 2%/2. There was no noticeable correlation among the different QA methods. Our multi‐institutional study suggested that the CL was not a suitable metric for defining the tolerance level when the statistics of the sample group did not follow the normality and had a large standard deviation.</P><P>PACS number: 87.55.Qr</P>
-
Kim, Sung Min,Choi, Jung Eun,Hur, Wonhee,Kim, Jung‐,Hee,Hong, Sung Woo,Lee, Eun Byul,Lee, Joon Ho,Li, Tian Zhu,Sung, Pil Soo,Yoon, Seung Kew John Wiley and Sons Inc. 2017 Journal of cellular biochemistry Vol.118 No.8
<P><B>ABSTRACT</B></P><P>The epithelial‐mesenchymal transition (EMT) is involved in many different types of cellular behavior, including liver fibrosis. In this report, we studied a novel function of RAR‐related orphan receptor gamma (ROR‐γ) in hepatocyte EMT during liver fibrosis. To induce EMT in vitro, primary hepatocytes and FL83B cells were treated with TGF‐β1. Expression of ROR‐γ was analyzed by Western blot in the fibrotic mouse livers and human livers with cirrhosis. To verify the role of ROR‐γ in hepatocyte EMT, we silenced ROR‐γ in FL83B cells using a lentiviral short hairpin RNA (shRNA) vector. The therapeutic effect of ROR‐γ silencing was investigated in a mouse model of TAA‐induced fibrosis by hydrodynamic injection of plasmids. ROR‐γ expression was elevated in hepatocyte cells treated with TGF‐β1, and ROR‐γ protein levels were elevated in the fibrotic mouse livers and human livers with cirrhosis. Knockdown of ROR‐γ resulted in the attenuation of TGF‐β1‐induced EMT in hepatocytes. Strikingly, ROR‐γ bound to ROR‐specific DNA response elements (ROREs) in the promoter region of TGF‐β type I receptor (Tgfbr1) and Smad2, resulting in the downregulation of Tgfbr1 and Smad2 after silencing of ROR‐γ. Therapeutic delivery of shRNA against ROR‐γ attenuated hepatocyte EMT and ameliorated liver fibrosis in a mouse model of TAA‐induced liver fibrosis. Overall, our results suggest that ROR‐γ regulates TGF‐β‐induced EMT in hepatocytes during liver fibrosis. We suggest that ROR‐γ may become a potential therapeutic target in treating liver fibrosis. J. Cell. Biochem. 118: 2026–2036, 2017. © 2016 The Authors. <I>Journal of Cellular Biochemistry</I> Published by Wiley Periodicals Inc.</P>
-
Assessment of potential jaw‐tracking advantage using control point sequences of VMAT planning
Kim, Jung‐,in,Park, Jong Min,Park, So‐,Yeon,Choi, Chang Heon,Wu, Hong‐,Gyun,Ye, Sung‐,Joon unknown 2014 Journal of applied clinical medical physics Vol.15 No.2
<P>This study aims to evaluate the potential jaw‐tracking advantage using control point sequences of volume volumetric‐modulated arc therapy (VMAT) planning. VMAT plans for patients with prostate and head and neck (H&N) cancers were converted into new static arc (SA) plans. The SA plan consisted of a series of static fields at each control point of the VMAT plan. All other machine parameters of the SA plan were perfectly identical to those of the original VMAT plan. The jaw‐tracking static arc (JTSA) plans were generated with fields that closed the jaws of each SA field into the multileaf collimators (MLCs) aperture. The dosimetric advantages of JTSA over SA were evaluated in terms of a dose‐volume histogram (DVH) of organ at risk (OAR) after renormalizing both plans to make the same target coverage. Both plans were delivered to the MatriXX‐based COMPASS system for 3D volume dose verification. The average jaw size reduction of the JTSA along the X direction was 3.1±0.9 cm for prostate patients and 6.9±1.9 cm for H&N patients. For prostate patients, the organs far from the target showed larger sparing (3.7%—8.1% on aver‐age) in JTSA than the organs adjacent to the target (1.1%—1.5%). For the H&N plans, the mean dose reductions for all organs ranged from 4.3% to 11.9%. The dose reductions were more significant in the dose regions of <SUB>D80</SUB>,<SUB>D90</SUB>, and <SUB>D95</SUB> than the dose regions of <SUB>D5</SUB>,<SUB>D10</SUB>, and <SUB>D20</SUB> for all patients. Likewise, the deliverability and reproducibility of jaw‐tracking plan were validated. The measured dosimetric advantage of JTSA over SA coincided with the calculated one above.</P><P>PACS numbers: 87.55.D‐, 87.55.ne</P>
-
Associations of serotonergic genes with poststroke emotional incontinence
Kim, Jae‐,Min,Stewart, Robert,Kang, Hee‐,Ju,Bae, Kyung‐,Yeol,Kim, Sung‐,Wan,Shin, Il‐,Seon,Kim, Joon‐,Tae,Park, Man‐,Seok,Cho, Ki‐,Hyun,Yoon, Jin‐ John Wiley Sons, Ltd 2012 INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Vol.27 No.8
<P><B>Objectives</B></P><P>Poststroke emotional incontinence (PSEI) has been associated with serotonergic dysfunction. Polymorphisms of serotonin transporter (5‐HTT) and serotonin 2a receptor (5‐HTR2a) genes may regulate serotonergic signaling at brain synapses, and this study was to investigate associations with PSEI in an East Asian population.</P><P><B>Methods</B></P><P>In 276 stroke cases, PSEI was diagnosed by Kim's criteria. Covariates included age, gender, education, history of depression or stroke, current depression, and stroke severity and location. Genotypes were ascertained for 5‐HTT gene‐linked promoter region (5‐HTTLPR), serotonin transporter intron 2 variable number tandem repeat, 5‐HTR2a 1438A/G, and 5‐HTR2a 102 T/C. Associations with PSEI were estimated by using logistic regression models, and gene–gene interactions were investigated by using the generalized multifactor dimensionality reduction method.</P><P><B>Results</B></P><P>PSEI was present in 37 (13.4%) patients. The 5‐HTT gene‐linked promoter region <I>s</I>/<I>s</I> genotype was independently associated with PSEI. No associations with STin2 VNTR and 5‐HTR2a genes were found, and no significant gene–gene interactions were identified.</P><P><B>Conclusions</B></P><P>Stroke patients with 5‐HTTLPR <I>s</I> allele had higher susceptibility to PSEI, which underlines the potential role of serotonergic pathways in its etiology. Copyright © 2011 John Wiley & Sons, Ltd.</P>
-
Park, Yang‐,Kyun,Son, Tae‐,geun,Kim, Hwiyoung,Lee, Jaegi,Sung, Wonmo,Kim, Il Han,Lee, Kunwoo,Bang, Young‐,bong,Ye, Sung‐,Joon John Wiley and Sons Inc. 2013 Journal of applied clinical medical physics Vol.14 No.5
<P>Phase‐based respiratory‐gated radiotherapy relies on the reproducibility of patient breathing during the treatment. To monitor the positional reproducibility of patient breathing against a 4D CT simulation, we developed a real‐time motion verification system (RMVS) using an optical tracking technology. The system in the treatment room was integrated with a real‐time position management system. To test the system, an anthropomorphic phantom that was mounted on a motion platform moved on a programmed breathing pattern and then underwent a 4D CT simulation with RPM. The phase‐resolved anterior surface lines were extracted from the 4D CT data to constitute 4D reference lines. In the treatment room, three infrared reflective markers were attached on the superior, middle, and inferior parts of the phantom along with the body midline and then RMVS could track those markers using an optical camera system. The real‐time phase information extracted from RPM was delivered to RMVS via in‐house network software. Thus, the real‐time anterior‐posterior positions of the markers were simultaneously compared with the 4D reference lines. The technical feasibility of RMVS was evaluated by repeating the above procedure under several scenarios such as ideal case (with identical motion parameters between simulation and treatment), cycle change, baseline shift, displacement change, and breathing type changes (abdominal or chest breathing). The system capability for operating under irregular breathing was also investigated using real patient data. The evaluation results showed that RMVS has a competence to detect phase‐matching errors between patient's motion during the treatment and 4D CT simulation. Thus, we concluded that RMVS could be used as an online quality assurance tool for phase‐based gating treatments.</P><P>PACS number: 87.55.Qr</P>
-
Ko, Young‐,Ho,Kim, Je‐,Hyung,Jin, Li‐,Hua,Ko, Suk‐,Min,Kwon, Bong‐,Joon,Kim, Joosung,Kim, Taek,Cho, Yong‐,Hoon WILEY‐VCH Verlag 2011 ADVANCED MATERIALS Vol.23 No.45
<P>Electrically driven hybrid light‐emitting diodes (LEDs) consisting of quantum dots, wires, and wells based on the nanometer‐sized pyramid GaN structure are reported by Taek Kim, Yong‐Hoon Cho, and co‐workers on page 5364. The LEDs exhibit mixed emissions from InGaN quantum dots, wires, and wells formed at the tops, edges, and sidewalls of the pyramids, respectively. The hybrid LEDs containing low‐dimensional quantum structures provide a broad‐band, highly efficient visible lighting source. </P>
-
Jo, Nam Hyun,Kim, Jung Young,El‐,Gamal, Mohammed I.,Choi, Won‐,Kyoung,Park, Jin‐,Hun,Kim, Eun Jung,Cho, Jung‐,Hyuck,Ha, Hyun‐,Joon,Choi, Tae Hyun,Oh, Chang‐,Hyun John Wiley Sons, Ltd. 2011 Journal of labelled compounds & radiopharmaceutica Vol.54 No.2
<P><B>Abstract</B></P><P>Synthesis, radiolabelling, and <I>in vitro</I> evaluation of a new <SUP>125</SUP>I‐labelled iodouracil hexitol nucleoside analogue are reported. The target compound was successfully synthesized by an iodination–destannylation method and then purified by reverse phase HPLC. The radiochemical purity of the product was >99% with decay‐corrected yields of 48±3%. <I>In vitro</I> cellular uptake testing was carried out using MCA and MCA‐tk cell lines for comparison of compound 1 with [<SUP>18</SUP>F]FHBG. The newly synthesized compound 1 showed higher accumulation in herpex simplex virus type 1 thymidine kinase (HSV1‐tk) gene expression cell line (MCA‐tk cell line) than in the wild type MCA cell line compared with [<SUP>18</SUP>F]FHBG. The MCA‐tk to MCA cellular uptake ratio for compound 1 was higher than that of [<SUP>18</SUP>F]FHBG from 2 h after incubation. The radioiodine‐labelled compound 1 (I‐125, <I>t</I><SUB>1/2</SUB>=59.37 days) has a longer physical half‐life than F‐18‐(<I>t</I><SUB>1/2</SUB>=110 min) labelled FHBG. Radioiodine‐labelled compound 1 could be used for monitoring gene expression for a long time. The selectivity for MCA‐tk cell line makes compound 1 a promising imaging agent for HSV1‐tk expression. Copyright © 2010 John Wiley & Sons, Ltd.</P>
-
Min, Cheon‐,Ki,Wikesjö,, Ulf M. E.,Park, Jung‐,Chul,Chae, Gyung‐,Joon,Pippig, Susanne D.,Bastone, Patrizia,Kim, Chang‐,Sung,Kim, Chong‐,Kwan Blackwell Publishing Ltd 2011 Journal of Clinical Periodontology Vol.38 No.3
<P>Min C‐K, Wikesjö UME, Park J‐C, Chae G‐J, Pippig SD, Bastone P, Kim C‐S, Kim C‐K. Wound healing/regeneration using recombinant human growth/differentiation factor‐5 in an injectable poly‐lactide‐co‐glycolide‐acid composite carrier and a one‐wall intra‐bony defect model in dogs. J Clin Peridontol 2011; 38: 261–268. 38: 261–268. doi: 10.1111/j.1600‐051X.2010.01691.x.</P><P><B>Abstract</B></P><P><B>Objective: </B> The purpose of this study was to evaluate the effect of recombinant human growth/differentiation factor‐5 (rhGDF‐5) on periodontal wound healing/regeneration using an injectable poly‐lactide‐co‐glycolide‐acid (PLGA) composite carrier and an established defect model.</P><P><B>Methods: </B> Bilateral 4 × 5 mm (width × depth) one‐wall, critical‐size, intra‐bony periodontal defects were surgically created at the second and the fourth mandibular pre‐molar teeth in 15 Beagle dogs. The animals were randomized to receive (using a split‐mouth design; defect sites in the same jaw quadrant getting the same treatment) rhGDF‐5 high dose (188 <I>μ</I>g/defect) <I>versus</I> sham‐surgery control (five animals), rhGDF‐5 mid dose (37 <I>μ</I>g/defect) <I>versus</I> carrier control (five animals), and rhGDF‐5 low dose (1.8 <I>μ</I>g/defect) <I>versus</I> treatment reported elsewhere (five animals). The animals were euthanized for histometric analysis following an 8‐week healing interval.</P><P><B>Results: </B> Clinical healing was uneventful. The rhGDF‐5/PLGA construct was easy to assemble and apply. The rhGDF‐5 high dose supported significantly increased bone formation compared with the low‐dose, sham‐surgery, and carrier controls (<I>p</I><0.05) and induced significantly increased cementum formation compared with the controls (<I>p</I><0.05). Root resorption/ankylosis or other aberrant healing events were not observed.</P><P><B>Conclusion: </B> rhGDF‐5 appears to effectively support periodontal wound healing/regeneration in a dose‐dependent order; the PLGA composite appears to be an effective ease‐of‐use candidate for carrier technology.</P>
-
Song, Sun Ok,Kim, Kwang Joon,Lee, Byung‐,Wan,Kang, Eun Seok,Cha, Bong Soo,Lee, Hyun Chul Wiley-Blackwell 2014 Journal of diabetes investigation Vol.5 No.5
<P><B>Abstract</B></P><P><B>Aims/Introduction</B></P><P>We assessed the tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese Korean participants with type 2 diabetes. We also evaluated the characteristics of participants who respond adequately to glucagon‐like peptide‐1 (GLP‐1) analog therapy in terms of glycated hemoglobin (HbA1c) level reductions and weight loss.</P><P><B>Materials and Methods</B></P><P>This prospective, observational, single‐arm (exenatide b.i.d. in combination with both metformin and sulphonylurea), open‐label study of GLP‐1 analog treatment with close monitoring of metabolic parameters and weight changes was carried out for up to 22 weeks.</P><P><B>Results</B></P><P>Of the 110 enrolled obese participants, 37 participants dropped out during the 22‐week treatment period. A total of 73 participants completed the study (median age 55.0 years, interquartile range 44.0–65.0). The median duration of diabetes was 8.0 years (interquartile range 3.5–12.5) with a mean HbA1c value of 7.6% (interquartile range 7.00–8.55). The median body mass index was 30.78 kg/m<SUP>2</SUP> (interquartile range 27.89–33.92). After 22 weeks, median changes from baseline for HbA1c levels and weight were −0.7% and −3.0 kg, respectively, which were significant. No severe hypoglycemic events were observed. Multivariate regression analysis showed that C‐peptide values were a significant independent predictor for a reduction in HbA1c levels (β = 0.865, <I>P</I> = 0.018) with exenatide BID in combination with both sulphonylurea and metformin in obese Korean participants with type 2 diabetes and insulin naïveté.</P><P><B>Conclusions</B></P><P>Clinical and laboratory parameters, such as insulin naïveté and preserved β‐cell function, should be taken into consideration as important factors in the choice of GLP‐1 analog when predicting GLP‐1 analog responsiveness. This trial was registered with the local committee at Yonsei University in Korea (4‐2011‐0032).</P>
-
Kim, Joon‐,Sung,Chung, Won‐,Suk,Kim, Kyungkon,Kim, Dong Young,Paeng, Ki‐,Jung,Jo, Seong Mu,Jang, Sung‐,Yeon WILEY‐VCH Verlag 2010 Advanced Functional Materials Vol.20 No.20
<P><B>Abstract</B></P><P>Polymer solar cells (PSCs) are fabricated using a novel film deposition method, the electrostatic spray (e‐spray) technique. Stable atomization and uniform deposition of the polymer blend by e‐spray are achieved by manipulating the solution concentration, the solvent composition, and the electric field. The performance of PSCs is primarily influenced by the inherent film morphology of the e‐sprayed polymer‐blend active layers, which is significantly different from that of the conventional films that are formed using the spin‐coating (SC) method. The intrinsically formed interfacial boundaries between the e‐sprayed blend pancakes resist charge transport, which unfavorably influences device efficiency. The internal series resistance (<I>R</I><SUB>S</SUB>) of the PSCs that are formed using the e‐spray method (e‐spray‐PSC) is significantly reduced by a solvent vapor soaking (SVS) treatment in addition to the conventional thermodynamic nanomorphology controls. The detailed relationship between the morphologies (film morphology and internal nanomorphology) and the <I>R</I><SUB>S</SUB> is revealed using impedance spectroscopy. The performance of the e‐spray‐PSCs is comparable to those of the PSCs that are fabricated using the SC method under identical conditions. Therefore, the e‐spray method can be used to fabricate ultralow‐cost PSCs, because of the performance results combined with the intrinsic advantages that the e‐spray method is simple and has a low materials loss.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
